[go: up one dir, main page]

Orme et al., 1986 - Google Patents

Lack of evidence for a reduction in the efficacy of subcutaneous BCG vaccination in mice infected with nontuberculous mycobacteria

Orme et al., 1986

Document ID
6639743328037038226
Author
Orme I
Roberts A
Collins F
Publication year
Publication venue
Tubercle

External Links

Snippet

Subcutaneous BCG vaccination of mice several weeks after intravenous or subcutaneous infection with either M. avium or M. kansasii had no effect on the subsequent course of these nontuberculous mycobacterial infections. In some animals the growth of the BCG infection in …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Micro-organisms
    • Y10S435/822—Micro-organisms using bacteria or actinomycetales
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Similar Documents

Publication Publication Date Title
Orme Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines
CA2065286C (en) Treatment of chronic inflammatory conditions
Orme et al. Lack of evidence for a reduction in the efficacy of subcutaneous BCG vaccination in mice infected with nontuberculous mycobacteria
Sharquie BCG is a good immunotherapeutic agent for viral and autoimmune diseases: is it a new weapon against coronavirus (COVID-19)?
JPH07506093A (en) Mycobacterium vaccae to treat long-term autoimmune conditions
AU683835B2 (en) Therapeutic agent from mycobacterium vaccae and its use against HIV infection
Emery et al. An evaluation of mycophage therapy, chemotherapy and vaccination for control of Mycobacterium avium subsp. paratuberculosis infection
Levine et al. Development of vaccines for coccidioidomycosis
Božić et al. Levamisole mucosal adjuvant activity for a live attenuated Escherichia coli oral vaccine in weaned pigs
CA2064029C (en) Use of mycobacterium vaccae in the prevention of aids
CA2273848C (en) Mycobacterium vaccae for down-regulation of the th2 activity of the immune system
Collins Kinetics of the delayed-type hypersensitivity response in tuberculous guinea pigs and mice tested with several mycobacterial antigen preparations
KANAI et al. Studies on the reinfection in experimental tuberculosis of guinea pigs
Pugh et al. Experimentally induced infectious bovine keratoconjunctivitis: potentiation of a Moraxella bovis pilus vaccine's immunogenicity by vaccination with Mycobacterium paratuberculosis bacterin
Sharp et al. Studies of arthritis and other lesions induced in rats by injection of mycobacterial adjuvant. IV. Examination of tissues and fluids for infectious agents
Compton Sensitization and immunization with bacteriophage in experimental plague
Nigam et al. Anatomy and physiology of ageing 9: the immune system
US6596282B1 (en) Treatment of chronic viral infections with M. vaccae
Hepper et al. Immune responsiveness in mice heavily infected with Mycobacterium kansasii
US6878377B2 (en) Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
Talwar et al. Present approaches to immunotherapy and immunoprophylaxis for leprosy
Parant et al. Biological Properties of Non-Toxic Water-Soluble Immunoadjuvants from Mycobacterial Cells
Al-Samarrai et al. Immunity in syphilis. Studies in active immunity.
Nishihara et al. Immunogenicity of gamma-irradiated Mycobacterium tuberculosis H37Rv (GIV) in mice
Crowle Tubercle bacillary extracts immunogenic for mice 5. Specificity of tuberculo-immunity induced by trypsin extracts of tubercle bacilli